---
figid: PMC3621011__nihms408962f1
figlink: /pmc/articles/PMC3621011/figure/F1/
number: Figure 1
caption: Multiple strategies have been employed to pharmacologically target the VEGF
  signaling pathway. One anti-VEGF monoclonal antibody has been developed (bevacizumab).
  Multiple tyrosine kinase inhibitors (TKIs) target the intracellular kinase domain
  on the VEGF receptors, as well as on other important tyrosine kinases. Five currently
  approved VSP inhibitors fall into this category (sunitinib, sorafenib, axitinib,
  pazopanib, and vandetanib). Numerous other TKIs are in various stages of development
  or trials. Other approaches to VSP inhibition that are currently in development
  or clinical trials include a soluble VEGF receptor, or VEGF-Trap, and a monoclonal
  antibody generated against VEGFR2.
pmcid: PMC3621011
papertitle: 'Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors:
  Emerging Evidence and Evolving Perspectives.'
reftext: Steven M. Bair, et al. Trends Cardiovasc Med. ;23(4):104-113.
pmc_ranked_result_index: '58703'
pathway_score: 0.9551969
filename: nihms408962f1.jpg
figtitle: 'Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors:
  Emerging Evidence and Evolving Perspectives'
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3621011__nihms408962f1.html
  '@type': Dataset
  description: Multiple strategies have been employed to pharmacologically target
    the VEGF signaling pathway. One anti-VEGF monoclonal antibody has been developed
    (bevacizumab). Multiple tyrosine kinase inhibitors (TKIs) target the intracellular
    kinase domain on the VEGF receptors, as well as on other important tyrosine kinases.
    Five currently approved VSP inhibitors fall into this category (sunitinib, sorafenib,
    axitinib, pazopanib, and vandetanib). Numerous other TKIs are in various stages
    of development or trials. Other approaches to VSP inhibition that are currently
    in development or clinical trials include a soluble VEGF receptor, or VEGF-Trap,
    and a monoclonal antibody generated against VEGFR2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - PDGFB
  - ARNT2
  - HIF3A
  - MAP2K1
  - ARNTL
  - RAF1
  - VEGFD
  - PGF
  - ARAF
  - ARNT
  - BRAF
  - EPAS1
  - PDGFD
  - PDGFA
  - PDGFRB
  - KDR
  - MAPK3
  - MAPK1
  - HIF1A
  - FLT4
  - VEGFC
  - KIT
  - FLT1
  - PDGFC
  - VEGFA
  - PDGFRA
  - VEGFB
  - Cancer
genes:
- word: MEK,
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: MEK,
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: VEGFR1,3
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: c-Kit
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: VEGFR1,3
  symbol: VEGFR1
  source: hgnc_alias_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
